Company Valuation: Xcell Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2024 2025
Market Cap 1 44,384 28,726
Change - -35.28%
Enterprise Value (EV) 1 41,283 27,307
Change - -33.86%
P/E -4.26x -1.77x
PBR 4.87x 4.02x
PEG 0.47x 1.06x
Capitalization / Revenue 22.9x 14.7x
EV / Revenue 21.3x 14x
EV / EBITDA -5.38x -2.99x
EV / EBIT -4.42x -2.52x
EV / FCF -8.13x -4.03x
FCF Yield -12.3% -24.8%
Dividend per Share 2 - -
Rate of return - -
EPS 2 -954 -938
Distribution rate - -
Net sales 1 1,934 1,949
EBITDA 1 -7,677 -9,148
EBIT 1 -9,330 -10,852
Net income 1 -9,543 -10,927
Net Debt 1 -3,100 -1,419
Reference price 2 4,065.00 1,661.00
Nbr of stocks (in thousands) 10,918 17,294
Announcement Date 3/20/25 3/19/26
1KRW in Million2KRW
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 13.11M
31.99x11.64x23.74x0.62% 1,002B
29.94x - - 2% 649B
31.86x7.4x15.38x2.76% 440B
19.06x4.64x11.51x2.86% 346B
19.62x5.13x12.72x3.16% 263B
20.69x4.25x12.14x2.08% 250B
24.87x6.52x11.97x2.57% 213B
13.02x4.72x9.85x3.87% 201B
-44.81x6.47x25.27x2.25% 182B
Average 16.25x 6.35x 15.32x 2.46% 354.37B
Weighted average by Cap. 23.18x 7.75x 17.28x 2.03%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. A373110 Stock
  4. Valuation Xcell Therapeutics Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!